Navigation Links
FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
Date:2/6/2008

ATLANTA, Feb. 6 /PRNewswire/ -- UCB today announced that the U.S. Food and Drug Administration (FDA) agreed to accept, for filing and review, a biologics license application (BLA) for Cimzia(R) (certolizumab pegol) for the treatment of adult patients with active rheumatoid arthritis (RA). Cimzia(R) is an investigational agent. If approved, Cimzia(R) will be the first and only PEGylated anti-TNF (Tumor Necrosis Factor) biologic therapy available for the treatment of rheumatoid arthritis.

"As a new anti-TNF, we believe that Cimzia(R) would provide an important new option for people living with this disease," said Olav Hellebo, President Inflammation Operations, UCB.

The BLA is based on data from more than 2,367 patients and includes three multi-center, placebo-controlled Phase III trials which were recently presented at the American College of Rheumatology (ACR) Annual Scientific Meeting.

In these studies, Cimzia(R), given with methotrexate, was shown to be significantly more effective than methotrexate alone for the inhibition of joint damage progression in patients with active RA as early as 24 weeks (RAPID 1 and RAPID 2). Cimzia(R) was shown to rapidly reduce the signs and symptoms of active RA with peak ACR50 and 70 responses achieved at 14 and 16 weeks. Improvement in physical function and quality of life measures were also seen for up to one year (RAPID 1). Further, Cimzia(R) administered as monotherapy showed significant improvement in signs and symptoms of RA from week 1, and this benefit was maintained through week 24 (Study 011). The most commonly occurring adverse reactions were headache, nasopharyngitis, and upper respiratory tract infections. Reported serious adverse reactions were infections (including tuberculosis) and malignancies (including lymphoma), consistent with findings from other trials in the anti-TNF class.

Preparation for submission of a Marketing Authorization Application (MAA) to the European Medicines Ag
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
2. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
5. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
6. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
7. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
8. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
9. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
10. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
11. AEterna Zentaris Announces Outcome of Managements Strategic Review

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)... , Fuel economy ratings for the new 2010 model ...onomy.gov web site, which Oak Ridge National Labo...ment of Energy and the U.S. Environmental Protecti... fuel economy list are hybrid electrics, led by th...st proves that hybrids have gone mainstream," said...
(Date:11/5/2009)...re/ -- The endangered black-footed ferrets inhabit...carnivore feeds on prairie dogs. The prairie dog...population die-offs in towns occur. The U.S. Fish...rret breeding program and has been releasing train...itat. Unfortunately, plague can sweep through and...
(Date:11/5/2009)...Call/ -- Imagenetix, Inc. (OTC Bulletin Board: IAG...t and CEO of Imagenetix, will be presenting the Co...e on Thursday, December 3rd, at 10:30 AM PST at th... ,, LD MICRO is a by-invitation only newsletter...s in the micro-cap space. Since 2002, the firm has...
(Date:11/5/2009)...er 5, 2009 at 4:30 p.m. Eastern Time , BOTHEL...- OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or ...udited financial results for the third quarter and... the Company,s highlights for the third quarter of...flect the operations of OncoGenex Technologies Inc...
Breaking Biology Technology:November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8
...er Provides Extensive Experience In Molecular Diag...h, Inc., a company revolutionizing spine care thro...logies, announced today that Roberto A. Macina, Ph...he company,s new Vice President of Research and De...eth Ward, M.D., Chairman and Chief Scientific Offi...
... Netherlands, February 24 ,Amsterdam Molecular The...f,human gene therapy, today reported its results f...clinical trial in LPL deficiency causes a delay of...GlyberaTM which is now expected H2 2009, - Posi...orijn resigned for personal reasons, - Start of...
...Colo., Feb. 23 The National Academy of Sciences (...ebruary 18, 2009 finds deficiencies in the nation,...rms and new research. The report also calls for t...nes for quality control, proficiency testing, cert...aspects of forensic science. , , The report notes...
Other Biology Technology:Axial Biotech Appoints Dr. Roberto Macina to Vice President of Research and Development 2Amsterdam Molecular Therapeutics Reports Full Year Results 2008 2Amsterdam Molecular Therapeutics Reports Full Year Results 2008 3Strengthening Forensic Toxicology in the United States: The American Board of Forensic Toxicology Response to the National Academy of Sciences Recommendations 2
(Date:11/4/2009)... Lowly bacteria, it turns out, hold the power to h...around the world clean up toxic waste on test site... RDX, were invented back in World War II and have ...e high-energy compounds are often used to propel t... TNT. , But with increased knowledge of their ...
(Date:11/4/2009)...LEY, Calif., Oct. 19 Spectros, dev...ing and imaging devices which shed light on life-t...igned exclusive distribution deals for both its T-...arkets covered include Australia, New Zealand, Th...name, Italy, France, Spain, Portugal, Poland, Gree...
(Date:11/4/2009)...ss., Oct. 20 Aware, Inc.... technology and biometrics software, today reporte...eptember 30, 2009. ,, Michael Tzannes, Aware,...lier today, we announced an agreement to sell our ... new fabless semiconductor company being spun out ...
Breaking Biology News(10 mins):Genomic research will enable greener cleanup of military explosive test sites 2Spectros Signs New International Distribution Deals 2Aware, Inc. Reports Third Quarter 2009 Financial Results 2Aware, Inc. Reports Third Quarter 2009 Financial Results 3Aware, Inc. Reports Third Quarter 2009 Financial Results 4Aware, Inc. Reports Third Quarter 2009 Financial Results 5Aware, Inc. Reports Third Quarter 2009 Financial Results 6Aware, Inc. Reports Third Quarter 2009 Financial Results 7Award Winning Medical Technology From Germany 5432 1Award Winning Medical Technology From Germany 5432 2Award Winning Medical Technology From Germany 5432 3MicroRNA Biomarkers Provide Reliable Diagnosis from Blood Samples 5428 1MicroRNA Biomarkers Provide Reliable Diagnosis from Blood Samples 5428 2U S Patent Issued for Champions Biotechnologys Lead Oncology Drug 5424 1U S Patent Issued for Champions Biotechnologys Lead Oncology Drug 5424 2U S Patent Issued for Champions Biotechnologys Lead Oncology Drug 5424 3
...inked to genetic mutations, stunted growth and dec...rramatta River, the main tributary of Sydney Harbo...nting evidence that toxic sediments and seaweeds i...eatures. , The new findings, published in the jou...enetic mutations among crustaceans ( Melita plumul...
...alcohol syndrome are slight but classic: facial ma...ll eye openings and a short nose. , Researchers w...gure out how much alcohol it takes during what poi...g problems. , They have good evidence that just a... weeks of fetal life, typically before a woman kno...
...chers at the UC Davis M.I.N.D. Institute and The C...rgest study to date describing the medical and psy...der in which males have two "X" and two "Y" chromo...dy, published in the June 15, 2008, issue of the ... offers treatment recommendations for men and boys...
Other Biology News:Heavy metal link to mutations, low growth and fertility among crustaceans in Sydney Harbor tributary 2Alcohol consumption can cause too much cell death, fetal abnormalities 2UC Davis researchers define characteristics, treatment options for XXYY syndrome 2UC Davis researchers define characteristics, treatment options for XXYY syndrome 3
... with HRP conjugated rabbit polyclonal detection a... coating antibody. • BUF040A contains rab...ding between the coating and detection antibodies....ewly conjugated antibodies, to reconstitute lyophi...
...el piece, we can identify it using MALDI-TOF/TOF m...duce a mixture of peptides. The molecular weights ..., and the amino acid sequences of the top 10 peaks...ALDI-TOF/TOF. The masses and sequences will be use...
OmniSlide Heated Wash Module from Thermo Scientific
Factor Xa Protease from QIAGEN
Biology Products: